Shanghai Haoyuan Chemexpress Co., Ltd.

Shanghai Stock Exchange 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 14.63%

Shanghai Haoyuan Chemexpress Co., Ltd. EBITDA Margin is 14.63% for the year ending December 31, 2023, a -35.82% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Shanghai Haoyuan Chemexpress Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was 22.80%, a -19.50% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 28.32%, a 10.52% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was 25.63%, a 11.69% change year over year.
Shanghai Haoyuan Chemexpress Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 22.95%, a 118.84% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shanghai Stock Exchange: 688131.SS

Shanghai Haoyuan Chemexpress Co., Ltd.

CEO	Mr. Baofu Zheng
IPO Date	June 8, 2021
Location	China
Headquarters	No. 3 Building, No. 1999
Employees	3,370
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

Shanghai Haoyuan Chemexpress Co., Ltd. researches and develops pharmaceutical intermediates and small molecule drugs. It manufactures APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.

Key trends

Past 5 years